atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO and co-founder Dr Srinivas Rao talked with Proactive's Stephen Gunnion about the promising results in strategic investee Beckley Psytech’s Phase 2a study of BPL-003 for alcohol use disorder.
Rao highlighted the significant unmet need in treating alcohol use disorder (AUD), which affects approximately 400 million people globally and contributes to 3 million deaths per year. The Phase 2a trial, though small with 12 participants, yielded promising results. Patients received a single dose of BPL-003 alongside cognitive behavioral therapy, leading to a 50% abstinence rate over three months. Additionally, heavy drinking days were reduced from 56% to 13%, while abstinent days increased from 33% to 81%.
Looking ahead, atai Life Sciences is anticipating data from a larger Phase 2b study. Rao explained that BPL-003, a 5-MeO-DMT benzoate nasal spray, is being evaluated for its potential to provide long-lasting therapeutic effects with a single administration. This approach contrasts with existing treatments like Esketamine, which require frequent dosing.
Rao emphasized that shorter-duration psychedelic treatments could ease the burden on patients and healthcare providers. By reducing the need for frequent visits, these therapies could make mental health treatment more accessible and scalable.
To stay updated on atai Life Sciences' research, subscribe to Proactive’s YouTube channel, like this video, and enable notifications for future updates.
#ataiLifeSciences #PsychedelicTherapy #MentalHealth #AlcoholUseDisorder #BPL003 #DepressionTreatment #PharmaceuticalResearch #MedicalBreakthrough #InvestorNews #Biotech